Collaboration Agreements

1,928 Contracts & Agreements

Collaboration agreements include contracts that define joint initiatives between a company and other parties.

Browse Collaboration Agreements by Industry

Aerospace & Defense (1 contract from 1 company)
Air Freight & Logistics (2 | 1)
Auto Components (2 | 1)
Automobiles (1 | 1)
Biotechnology (1,168 | 294)
Chemicals (8 | 3)
Communications Equipment (2 | 1)
Construction & Engineering (1 | 1)
Consumer Finance (5 | 2)
Diversified Consumer Services (4 | 3)
Electrical Equipment (21 | 5)
Electronic Equipment, Instruments & Components (5 | 1)
Energy Equipment & Services (4 | 3)
Entertainment (3 | 2)
ETFs (9 | 2)
Food Products (1 | 1)
Health Care Equipment & Supplies (106 | 40)
Health Care Providers & Services (7 | 6)
Health Care Technology (4 | 3)
Hotels, Restaurants & Leisure (1 | 1)
Household Durables (3 | 1)
Household Products (1 | 1)
Independent Power & Renewable Electricity Producers (1 | 1)
Interactive Media & Services (1 | 1)
Internet & Direct Marketing Retail (1 | 1)
Life Sciences Tools & Services (26 | 13)
Machinery (1 | 1)
Media (1 | 1)
Metals & Mining (6 | 3)
Oil, Gas & Consumable Fuels (5 | 3)
Personal Products (2 | 1)
Pharmaceuticals (231 | 115)
Semiconductors & Semiconductor Equipment (8 | 5)
Software (4 | 4)
SPACs, Investment, & Acquisition Companies (11 | 5)
Specialty Retail (1 | 1)
Unassigned Industry (269 | 123)

Recent Contracts

Addendum to Collaboration Agreement dated December 27, 2021, by and between Enea Angelo Trevisan and Ealixir Hispania, S.L.U, dated April 28, 2023 (Ealixir, Inc., Filed With SEC on April 3, 2024)
Collaboration Agreement, by and between Enea Angelo Trevisan and Ealixir Hispania, S.L.U, dated December 27, 2021 (Ealixir, Inc., Filed With SEC on April 3, 2024)
Waiver, Confirmation and Agreement Regarding Research Collaboration effective December 31, 2023, between Whitehead Institute for Biomedical Research and the Registrant, relating... (Omega Therapeutics, Inc., Filed With SEC on March 28, 2024)
Waiver, Confirmation and Agreement Regarding Research Collaboration effective December 31, 2023, between Whitehead Institute for Biomedical Research and the Registrant, relating... (Omega Therapeutics, Inc., Filed With SEC on March 28, 2024)
Collaboration and Option Agreement by and between Senti Biosciences, Inc., and Celest Therapeutics (Shanghai) Co. Ltd., dated November 6, 2023 (Dynamics Special Purpose Corp., Filed With SEC on March 21, 2024)
Research Collaboration and Co-Development Agreement, dated as of November 9, 2022, by and between Nextcure, Inc. and LegoChem Biosciences, Inc (NextCure, Inc., Filed With SEC on March 21, 2024)
Strategic Collaboration Agreement, dated January 3, 2024, by and between Foresight Diagnostics, Inc. and the Registrant (Allogene Therapeutics, Inc., Filed With SEC on March 14, 2024)
Amended and Restated Collaboration and License Agreement, dated January 17, 2024, by and between the Registrant and Notch Therapeutics Inc (Allogene Therapeutics, Inc., Filed With SEC on March 14, 2024)
Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Entrada Therapeutics, Inc., Filed With SEC on March 13, 2024)
Research Collaboration Agreement, dated as of June 7, 2023, by and between the Company and PoloMar Health (PaxMedica, Inc., Filed With SEC on March 11, 2024)
Amendment No. 2, dated February 1, 2024, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT... (RAPT Therapeutics, Inc., Filed With SEC on March 7, 2024)
First Amendment to the Collaboration and License Agreement, dated November 7, 2023, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Poseida Therapeutics, Inc., Filed With SEC on March 7, 2024)
Letter Agreement Terminating Development Collaboration and License Agreement between registrant and Socit des Produits Nestl S.A. (f/k/a NESTEC S.A.), dated October 26, 2023 (DBV Technologies S.A., Filed With SEC on March 7, 2024)
First Amendment to the Amended and Restated License and Collaboration Agreement, dated June 14, 2023, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn... (INOVIO PHARMACEUTICALS, INC., Filed With SEC on March 6, 2024)
Amended and Restated Research Collaboration and Option Agreement by and between Bayer AG and the Registrant, dated November 8, 2023 (RECURSION PHARMACEUTICALS, INC., Filed With SEC on February 29, 2024)
Amendment no. 14 dated October 31, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Sarepta Therapeutics, Inc., Filed With SEC on February 28, 2024)
Amendment no. 13 dated August 31, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Sarepta Therapeutics, Inc., Filed With SEC on February 28, 2024)
Amendment no. 12 dated July 28, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Sarepta Therapeutics, Inc., Filed With SEC on February 28, 2024)
Amendment no. 11 dated June 23, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Sarepta Therapeutics, Inc., Filed With SEC on February 28, 2024)
Amendment No. 1 Collaboration and License Agreement between the Registrant and Gilead Sciences, Inc (Arcellx, Inc., Filed With SEC on February 28, 2024)
License and Collaboration Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023 (Voyager Therapeutics, Inc., Filed With SEC on February 28, 2024)
Research Collaboration and License Agreement, dated November 27, 2023, by and between Bristol-Myers Squibb Company and the Registrant (Avidity Biosciences, Inc., Filed With SEC on February 28, 2024)
License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics (MANNKIND CORP, Filed With SEC on February 27, 2024)
Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd (FATE THERAPEUTICS INC, Filed With SEC on February 26, 2024)
Amendment No. 3 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated January 2 (Arcus Biosciences, Inc., Filed With SEC on February 21, 2024)
Clinical Trial Collaboration and Supply Agreement by and between Gilead Sciences, Inc. and IDEAYA Biosciences, Inc. dated as of November 29, 2023 (IDEAYA Biosciences, Inc., Filed With SEC on February 20, 2024)
Fifth Amendment to Collaboration and License Agreement, dated November 3, 2023, by and between the Registrant and Genzyme Corporation (Nurix Therapeutics, Inc., Filed With SEC on February 15, 2024)
Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC) (DEXCOM INC, Filed With SEC on February 8, 2024)
Collaboration Agreement by and between the Company and Integrated Path Communications LLC dated as of June 15, 2023 (Tesspay Inc., Filed With SEC on January 26, 2024)
Business Collaboration Agreement, dated January (PropTech Acquisition Corp, Filed With SEC on January 25, 2024)
License and Collaboration Agreement, dated December 29, 2021, between Kyverna Therapeutics, Inc. and Intellia Therapeutics, Inc (Kyverna Therapeutics, Inc., Filed With SEC on January 16, 2024)
Clinical Collaboration Agreement, by and between the Registrant and Beijing InnoCare Pharma Tech Co., Ltd., dated June 23, 2023 (ArriVent Biopharma, Inc., Filed With SEC on January 5, 2024)
Research Collaboration Agreement, dated December 21, 2021, by and between Aarvik Therapeutics, Inc. and the Registrant, as amended by Amendment No. 1, effective June 30, 2023 (ArriVent Biopharma, Inc., Filed With SEC on January 5, 2024)
Joint Clinical Collaboration Agreement, by and between the Registrant and Shanghai Allist Pharmaceuticals Co., Ltd., dated December 24, 2021 (ArriVent Biopharma, Inc., Filed With SEC on January 5, 2024)
First Amendment to the License and Collaboration Agreement, dated September 15, 2022, between Kissei Pharmaceutical Co., Ltd. and the Registrant (CG Oncology, Inc., Filed With SEC on January 2, 2024)
License and Collaboration Agreement, dated March 26, 2020, between Kissei Pharmaceutical Co., Ltd. and the Registrant (CG Oncology, Inc., Filed With SEC on January 2, 2024)
Amendment 1 to the Master Research Collaboration Agreement, dated November 29, 2023, by and between Neurogene Inc. and The University Court of The University of Edinburgh (AQUINOX PHARMACEUTICALS, INC, Filed With SEC on December 19, 2023)
Collaboration and License Agreement dated November 8, 2013, between Orient Europharma Co., LTD. and NeOnc Technologies, Inc (NEONC TECHNOLOGIES HOLDINGS, INC., Filed With SEC on December 18, 2023)
Collaboration and Option Agreement, dated August 12, 2022, by and between Q32 Bio Inc. and Horizon Therapeutics Ireland DAC (Homology Medicines, Inc., Filed With SEC on December 18, 2023)
Extension Agreement to the Master Framework Agreement for ETJ Collaboration, dated December 11, 2023, by and between Gevo, Inc. and Axens North America, Inc (Gevo, Inc., Filed With SEC on December 13, 2023)